Goodwill Pharma Nyrt. has built new storage facilities, an R&D&I laboratory, and a pharmaceutical plant in Szeged with a total investment of nearly HUF 5 billion (EUR 12.5 million).
The logistics center offers space for 4,000–5,000 pallets of medicines, while the production facility meets the latest pharmaceutical industry standards. Additionally, a pharmaceutical laboratory has been established to expand R&D activities, along with a new office building in downtown Szeged. Plans are also underway to build a medicinal plant processing facility.
The company is expected to soon list on the Budapest Stock Exchange, BÉT’s Standard Market. Goodwill Pharma aims to raise capital not only for technological development but also for future acquisitions.
With over 25 years of experience in the pharmaceutical industry, Goodwill Pharma focuses on the development and production of dietary supplements. It also focuses on pharmaceutical manufacturing, logistics, and distribution.
Serbia is the company’s largest export market. The company also operates subsidiaries in Croatia, Bosnia, Montenegro, Slovakia, Poland, Romania, and, since late last year, in Czechia and Austria.